Interim data to be reported for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Conference call to be held Monday ...

Relay Therapeutics announced updated interim clinical data for RLY-2608, an investigational inhibitor of PI3Kα designed for patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The ...

RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform Preclinically, achieved tumor regressions in vivo with significantly reduced impact on ...

ORLANDO, Fla. — Researchers presented early-phase trial results on RLY-2608, Relay Therapeutics’ next-generation PI3K inhibitor, at the American Association for Cancer Research annual meeting ...